Premium
Phase I study of cord blood‐derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma
Author(s) -
Shah Nina,
Li Li,
McCarty Jessica,
Kaur Indreshpal,
Yvon Eric,
Shaim Hila,
Muftuoglu Muharrem,
Liu Enli,
Orlowski Robert Z.,
Cooper Laurence,
Lee Dean,
Parmar Simrit,
Cao Kai,
Sobieiski Catherine,
Saliba Rima,
Hosing Chitra,
Ahmed Sairah,
Nieto Yago,
Bashir Qaiser,
Patel Krina,
Bollard Catherine,
Qazilbash Muzaffar,
Champlin Richard,
Rezvani Katy,
Shpall Elizabeth J.
Publication year - 2017
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14570
Subject(s) - hematology , multiple myeloma , medicine , transplantation , oncology , stem cell , cord blood , autologous stem cell transplantation , immunology , biology , genetics
Summary Multiple myeloma ( MM ) is a disease with known immune dysregulation. Natural killer ( NK ) cells have shown preclinical activity in MM . We conducted a first‐in‐human study of umbilical cord blood‐derived (CB) NK cells for MM patients undergoing high dose chemotherapy and autologous haematopoietic stem cell transplantation (auto‐HCT). Patients received lenalidomide (10 mg) on days −8 to −2, melphalan 200 mg/m 2 on day −7, CB‐NK cells on day −5 and auto‐HCT on day 0. Twelve patients were enrolled, three on each of four CB‐NK cell dose levels: 5 × 10 6 , 1 × 10 7 , 5 × 10 7 and 1 × 10 8 CB‐NK cells/kg. Ten patients had either high‐risk chromosomal changes or a history of relapsed/progressed disease. There were no infusional toxicities and no graft‐versus‐host disease. One patient failed to engraft due to poor autologous graft quality and was rescued with a back‐up autologous graft. Overall, 10 patients achieved at least a very good partial response as their best response, including eight with near complete response or better. With a median follow‐up of 21 months, four patients have progressed or relapsed, two of whom have died. CB‐NK cells were detected in vivo in six patients, with an activated phenotype (NKG2D + /NKp30 + ). These data warrant further development of this novel cellular therapy.